Cargando…

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

2′,2′-Difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum (cisplatin, CDDP) are active agents against ovarian cancer and non-small-cell lung cancer (NSCLC). CDDP acts by formation of platinum (Pt)–DNA adducts; dFdC by dFdCTP incorporation into DNA, subsequently leading to inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moorsel, C J A van, Pinedo, H M, Veerman, G, Bergman, A M, Kuiper, C M, Vermorken, J B, van der Vijgh, W J F, Peters, G J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363050/ https://www.ncbi.nlm.nih.gov/pubmed/10362105 http://dx.doi.org/10.1038/sj.bjc.6690452

Ejemplares similares

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines
por: Bergman, A M, et al.
Publicado: (2003)

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
por: Kroep, J R, et al.
Publicado: (2000)

Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo
por: Welters, M J P, et al.
Publicado: (1999)

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
por: Sørensen, J B, et al.
Publicado: (1999)

The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer
por: van Zweeden, A. A., et al.
Publicado: (2018)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
por: van Putten, J W G, et al.
Publicado: (2000)

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
por: Schlippe, M von, et al.
Publicado: (2001)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
por: Kooten, M Van, et al.
Publicado: (1999)

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001)

Cisplatin and CCNU synergism in spheroid cell subpopulations.
por: Durand, R. E.
Publicado: (1990)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
por: Zhou, Bo, et al.
Publicado: (2019)

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
por: Wachters, F M, et al.
Publicado: (2003)

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000)

Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts
por: Kolfschoten, G M, et al.
Publicado: (2000)

Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin
por: C̆emaz̆ar, M, et al.
Publicado: (1999)

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
por: Anderson, H, et al.
Publicado: (2000)

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
por: Zoli, W, et al.
Publicado: (1999)

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or Cytosine arabinoside
por: Neale, M H, et al.
Publicado: (1999)

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule
por: Boven, E, et al.
Publicado: (2005)

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
por: Yang, C H, et al.
Publicado: (2002)

A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer
por: Watanabe, Y, et al.
Publicado: (2001)

Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
por: van Ark-Otte, J., et al.
Publicado: (1998)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
por: Scheithauer, W, et al.
Publicado: (1999)

Human germ cell tumours: expression of γ-glutamyl transpeptidase and sensitivity to cisplatin
por: Hanigan, M H, et al.
Publicado: (1999)

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin
por: O’Neill, C F, et al.
Publicado: (1999)

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix
por: Wit, R de, et al.
Publicado: (1999)

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
por: Peelen, T, et al.
Publicado: (2000)

Anticancer properties of cannabidiol and Δ(9)-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines
por: Whynot, Erin G., et al.
Publicado: (2023)

Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
por: Los, G., et al.
Publicado: (1994)

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
por: Fosså, S D, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_2nqnlslgndtsflc5of8s75edtd